Clinical Trial Update: Veinplicity for Improved Venous Access: The VIVA Trial [Phase 3]

View source ↗

Summary

Phase 3 trial for Veinplicity in patients with difficult-to-access veins for intravenous cannulation has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Difficult-to-access Veins For Intravenous Cannulation

Drugs mentioned

• Veinplicity

Snippet

Sponsor: Physeon GmbH | Conditions: Difficult-to-access Veins for Intravenous Cannulation | Phase 3 | Status: TERMINATED